HNP-1: The Human Neutrophil Defensin That Kills Bacteria and Viruses — Structure, Function, and Clinical Potential
Human Neutrophil Peptide-1 (HNP-1) has broad-spectrum activity against bacteria and viruses and shows promise as an alternative to traditional antibiotics, though mass production and mechanism understanding remain challenges.
Quick Facts
What This Study Found
HNP-1, produced primarily by human neutrophils, exhibits broad-spectrum antimicrobial activity against both bacteria and viruses. The review identified several key aspects:
• HNP-1 combats pathogens without leading to the resistance patterns seen with traditional antibiotics
• The peptide has multiple functions beyond direct antimicrobial killing, including immune regulatory roles
• Mass production has been a major barrier to clinical use — microbial biosynthesis systems offer a cost-effective alternative to human extraction
• Recent studies have revealed HNP-1's endogenous bactericidal mechanism, advancing understanding of how it kills pathogens
• The peptide's gene expression, distribution, and regulatory elements controlling its production are now better understood
Key Numbers
How They Did This
This was a comprehensive narrative review examining published literature on HNP-1, covering its molecular structure, gene expression, tissue distribution, immune functions, antimicrobial mechanisms, biosynthesis methods, and potential clinical applications. The review integrated studies on both the basic biology of HNP-1 and applied research on production methods.
Why This Research Matters
Antibiotic resistance is one of the biggest threats to global health, with drug-resistant infections killing over a million people annually. HNP-1 represents a fundamentally different approach — using the body's own antimicrobial peptide as a therapeutic agent. Because HNP-1 kills bacteria by disrupting their membranes (rather than targeting specific proteins like antibiotics do), bacteria have much more difficulty developing resistance. If production challenges can be solved, HNP-1 could become a powerful weapon against drug-resistant infections.
The Bigger Picture
HNP-1 is part of the alpha-defensin family — one of the first lines of immune defense in the human body. The growing interest in developing antimicrobial peptides as alternatives to antibiotics has put HNP-1 in the spotlight. This review captures a field at a turning point: the biology of HNP-1 is increasingly understood, and production technology is catching up. Combined with the urgent need for new antimicrobial agents, HNP-1 is positioned as a leading candidate among human-derived antimicrobial peptides for clinical development.
What This Study Doesn't Tell Us
This is a narrative review that summarizes existing knowledge rather than presenting new data. The clinical application of HNP-1 remains theoretical — no human clinical trials are reported. The mass production challenge, while being addressed through microbial biosynthesis, has not been fully solved. The review may not cover all recent studies comprehensively. Additionally, antimicrobial peptides can have off-target effects (e.g., toxicity to host cells at high concentrations) that are not deeply explored.
Questions This Raises
- ?Can microbial biosynthesis produce HNP-1 at sufficient scale and purity for clinical use?
- ?Would systemically administered HNP-1 be safe, or would it need to be restricted to topical or localized applications?
- ?How does HNP-1's antimicrobial potency compare to other defensins and synthetic antimicrobial peptides in head-to-head studies?
Trust & Context
- Key Stat:
- Kills without resistance Unlike traditional antibiotics, HNP-1 combats bacteria through membrane disruption, making it extremely difficult for pathogens to develop resistance — a critical advantage in the antibiotic resistance crisis.
- Evidence Grade:
- This is a narrative review synthesizing the current state of knowledge on HNP-1. While comprehensive, it does not present original experimental data or apply systematic review methodology. It maps the field rather than testing specific hypotheses.
- Study Age:
- Published in 2025, this is a current review capturing the latest understanding of HNP-1 biology and recent advances in microbial biosynthesis methods for production.
- Original Title:
- HNP-1: From Structure to Application Thanks to Multifaceted Functions.
- Published In:
- Microorganisms, 13(2) (2025)
- Authors:
- Zhang, Jiaqi, Liu, Zhaoke, Zhou, Zhihao, Huang, Zile, Yang, Yifan, Wu, Junzhu, Liu, Yanhong
- Database ID:
- RPEP-14500
Evidence Hierarchy
Frequently Asked Questions
What is HNP-1 and where does it come from?
HNP-1 (Human Neutrophil Peptide-1) is a small antimicrobial peptide produced by neutrophils — the most abundant type of white blood cell in your body. When neutrophils encounter bacteria or viruses, they release HNP-1 to kill the invaders. It's one of your body's first-line chemical weapons against infection, and it's part of the defensin family of antimicrobial peptides.
Why can't bacteria develop resistance to HNP-1 like they do with antibiotics?
Traditional antibiotics target specific proteins inside bacteria, and bacteria can mutate those proteins to become resistant. HNP-1 works differently — it attacks the bacterial cell membrane itself, punching holes in it. Changing an entire membrane structure is extremely difficult for bacteria to achieve through simple mutations, making resistance development much less likely.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14500APA
Zhang, Jiaqi; Liu, Zhaoke; Zhou, Zhihao; Huang, Zile; Yang, Yifan; Wu, Junzhu; Liu, Yanhong. (2025). HNP-1: From Structure to Application Thanks to Multifaceted Functions.. Microorganisms, 13(2). https://doi.org/10.3390/microorganisms13020458
MLA
Zhang, Jiaqi, et al. "HNP-1: From Structure to Application Thanks to Multifaceted Functions.." Microorganisms, 2025. https://doi.org/10.3390/microorganisms13020458
RethinkPeptides
RethinkPeptides Research Database. "HNP-1: From Structure to Application Thanks to Multifaceted ..." RPEP-14500. Retrieved from https://rethinkpeptides.com/research/zhang-2025-hnp1-from-structure-to
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.